PPD will refer clients to Southern Research in return for seasonal flu assays and reagents.

PPD and Southern Research Institute are joining forces to offer clients a range of vaccine development services for pandemic and seasonal influenza. The companies expect to collaborate on client bids and projects.

Southern Research will transfer its seasonal influenza assays and reagents to PPD, strengthening PPD’s influenza vaccine testing services. In return, PPD will help build Southern Research’s preclinical influenza and clinical pandemic/highly pathogenic avian influenza testing business through client referrals.

“This key collaboration enhances PPD’s position as the first CRO to offer a comprehensive menu of vaccine assay-development and testing services to support vaccine clinical trials with faster, more cost-efficient laboratory solutions,” says Christine Dingivan, M.D., CMO of PPD. “Our agreement with Southern Research further expands our large collection of commercial vaccine assays with very important capabilities in the influenza vaccine field and enables us to expand our partnerships with influenza vaccine developers in the commercial, government, and nonprofit sectors.”

Nancy M. Gray, Ph.D., vp of corporate development, Southern Research Institute, adds, “By partnering with PPD, Southern Research has the opportunity to expand its client base for the well-recognized work our scientists perform in the influenza research field.”

Previous articleAbraxis Says NSCLC Phase III Trial Met Its Primary Endpoint
Next articleRecordati Reports U.S. Sanction of Treatment for Hyperammonemia due to NAGS Deficiency